<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             J Neurochem. 2010 March ; 112(6): 1593&#226;&#8364;&#8220;1604. doi:10.1111/j.1471-4159.2010.06568.x. <br />  <br />  <br />  <br />                            MKK6 binds regulates expression Parkinson&#226;&#8364;&#8482;s disease- <br />                            related protein LRRK2 <br />  <br />                            Cindy H. Hsu1, Diane Chan1, Elisa Greggio2, Shamol Saha1, Maria D. Guillily1, Andrew <br />                            Ferree1, Kesav Raghavan1, Grace C. Shen1, Lilach Segal1, Hoon Ryu3, Mark R. Cookson2, <br />                            Benjamin Wolozin1,* <br />                            1Department Pharmacology, Boston University School Medicine, Boston, MA 02118-2526 <br />  <br />                            2Laboratory    Neurogenetics, National Institute Aging, Bethesda, MD 20892 <br />                            3Department      Neurology, Boston University School Medicine, Boston, MA 02118-2526 <br />  <br />                            Abstract <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 Mutations leucine-rich repeat kinase 2 (LRRK2) prevalent causes late-onset Parkinson&#226;&#8364;&#8482;s <br />                                 disease (PD).  LRRK2 binds mitogen-activated protein kinase (MAPK) <br />                                 kinases MKK3, 6, 7, LRRK2 able phosphorylate MKK3, 6 7.  <br />                                 expression LRRK2 MKK6 increased steady state levels protein                                 observed expression protein  expression increased levels MKK6                                 membrane cytoplasm. increased expression LRRK2 MKK6 <br />                                 requires MKK6 activity. disease-linked LRRK2 mutations, G2019S, R1441C I2020T, <br />                                 enhance binding LRRK2 MKK6. interaction supported vivo studies                                 C. elegans. RNAi knockdown C. elegans endogenous orthologs MKK6 p38, sek-1 <br />                                 pmk-1, abolishes LRRK2-mediated protection mitochondrial stress. results <br />                                 confirmed deletion sek-1 C. elegans. data demonstrate MKKs                                 LRRK2 function similar biological pathways, support role LRRK2 modulating                                 cellular stress response. <br />  <br />  <br />                            Keywords <br />                                 MAP kinase; phosphorylation; C. elegans; JNK; p38; membrane <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            INTRODUCTION <br />                                             Parkinson&#226;&#8364;&#8482;s disease (PD) common neurodegenerative movement disorder <br />                                             (Olanow et al. 2009). majority PD cases sporadic, identification                                             genes responsible familial parkinsonism enhanced understanding                                             pathogenesis PD. Autosomal-dominant mutations leucine-rich repeat kinase 2 <br />                                             (LRRK2) particularly interesting associated sporadic PD                                             familial form PD resembles sporadic PD (Zimprich et al. 2004). majority                                             LRRK2 cases exhibit pathological findings consisting &#206;&#177;-synuclein inclusions,                                             pathological hallmark PD (Zimprich et al. 2004).  cases LRRK2 <br />                                             mutations exhibit pleiomorphic pathology, including tau inclusions, inclusions <br />                                             (Zimprich et al. 2004). <br />  <br />  <br />  <br />                            *Correspondence  Benjamin Wolozin, M.D., Ph.D., Department Pharmacology, Boston University School Medicine, 715 <br />                            Albany St, R-614, Boston, MA 02118-2526, 617-414-2652 (Phone), 617-414-2651 (Fax), bwolozin@bu.edu. <br />                             Hsu et al.                                                                                              Page 2 <br />  <br />  <br />                                            LRRK2 protein conserved domains including: leucine-rich domain (LRR), <br />                                            Roc GTPase domain, COR (carboxy-terminal Ras) domain, kinase domain,                                            WD40 domain carboxy-terminal (Zimprich et al. 2004, Greggio <span id='am-25' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-26' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-28' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-31' property="rdfs:label" content="AMP" datatype="xsd:string"></span>amp</span>; Cookson 2009). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            G2019S familial mutation leads increased LRRK2 autophosphorylation kinase <br />                                            activity (West et al. 2005, Smith et al. 2005, Smith et al. 2006, Greggio et al. 2006).                                            mutations appear affect kinase activity lesser extent (West et al. 2005, Smith et al. <br />                                            2005, Smith et al. 2006, Gloeckner et al. 2009, Jaleel et al. 2007). expression                                            mutants lead increased caspase-dependent toxicity primary neurons <br />                                            (Macleod et al. 2006, Iaccarino et al. 2007, Ho et al. 2009). Missense mutations causing <br />                                            disruption LRRK2 GTPase activity shown lead cell death (Ito et al. <br />                                            2007, Lewis et al. 2007, Li et al. 2007). addition, LRRK2 appears regulate neurite <br />                                            morphology rodents, human neuronal cell lines (Macleod et al. 2006, Plowey et al. <br />                                            2008).  exact mechanism LRRK2 lead pathogenesis PD <br />                                            remains critical unanswered question. <br />  <br />                                            kinase domain LRRK2 shares homology receptor interacting protein kinases <br />                                            (RIPs) mixed lineage kinases (MLKs) (Greggio &amp; Cookson 2009). RIP kinases,                                            RIP-1, mediate signaling death receptors, activate stress kinases (JNK p38) <br />                                            NF-kB (Festjens et al. 2007). RIP kinase family particularly interesting                                            light recent observations LRRK2 mediates signaling death receptor <br />                                            protein Fas binding protein (Ho et al. 2009). MLKs family serine/threonine protein <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            kinases function upstream MAPK signaling cascades (Silva et al. 2005).                                            MLK family kinases activate c-jun amino-terminal kinase (JNK) pathway                                            phosphorylating MAPK kinase 4 7 (MKK4 MKK7), p38 pathway                                            phosphorylating MAPK kinase 3 6 (MKK3 MKK6). MKKs                                            recruited multi-protein complex scaffold proteins JNK Interacting Proteins (JIPs) <br />                                            1&#226;&#8364;&#8220;3 (Gallo &amp; Johnson 2002). homology LRRK2, RIPs MLKs lead                                            hypothesize LRRK2 interact MKKs manner similar kinases. <br />  <br />                                            data demonstrate interactions LRRK2 MKK 3, 6, 7. observed                                            LRRK2 binds MKKs COR kinase domains, phosphorylates                                            MKKs. G2019S, R1441C I2020T LRRK2 mutations increase association                                            LRRK2 MKK6. Binding LRRK2 MKK6 associated increased levels                                            proteins plasma membrane cytoplasm, change dependent                                            activity MKK6. LRRK2 able phosphorylate MKK6. validated importance                                            MKK6 LRRK2 function mitochondrial stress using RNAi knockdown                                            deletion transgenic LRRK2 C. elegans. data suggest intriguing mechanism                                            MKK6 regulate function LRRK2, suggests role LRRK2                                            stress response. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               MATERIALS METHODS <br />                               Constructs <br />                                            Wild-type (WT) mutant LRRK2 V5 tagged constructs generated described <br />                                            Greggio et al. (Greggio et al. 2006). pathogenic, kinase dead, deletion LRRK2 <br />                                            constructs utilized study illustrated schematically Fig. S1. pRSV-Flag-MKK3, <br />                                            dominant negative pRSV-Flag-MKK3 (Ala), pcDNA3-Flag-MKK6, dominant negative <br />                                            pcDNA3-Flag-MKK6 (K82A), pcDNA3-Flag-MKK7, dominant negative pcDNA3- <br />                                            Flag-MKK7 (K82A) generous gifts Dr. Roger Davis (University                                            Massachusetts). Recombinant MKK3, 6 7 purchased R&amp;D Systems. <br />  <br />  <br />  <br />  <br />                                                 J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                                Page 3 <br />  <br />  <br />                               Cell culture <br />                                              HEK-293 HEK-293FT cells maintained DMEM (Invitrogen) supplemented                                              10% FBS (Atlanta Biologicals), 1&#195;&#8212; non-essential amino acids, penicillin (100 units/ml), NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              streptomycin (100 &#194;&#181;g/ml). Transfections performed using FuGENE 6.0 reagent (Roche <br />                                              Applied Science) HEK-293 cells Lipofectamine 2000 (Invitrogen) HEK-293FT <br />                                              cells. <br />  <br />                               Quantitative real-time PCR assay <br />                                              HEK-293 cells transfected LRRK2 constructs RNA extracted 8 hours <br />                                              post-transfection using Qiagene RNeasy mini kit. Intact RNA checked running                                              1.0% agarose gel quantified spectrometrically (NanoDrop ND-1000) proceeding <br />                                              subsequent steps. 1 &#194;&#181;g total RNA reverse-transcribed using iScript cDNA <br />                                              synthesis kit (Bio-Rad) according manufacturer&#226;&#8364;&#8482;s instructions. Real-time PCR                                              performed MyiQ&#226;&#8222;&#162; Detection (Bio-Rad) using iQ SYBR Green supermix. <br />                                              Expression levels target gene calculated 2-&#206;&#8221;&#206;&#8221;CT method (Livak &amp; <br />                                              Schmittgen 2001). analyses performed triplicates. Primers used c-jun                                              5&apos;-GGAACAGGTGGCACAGCTTAAACA-3&apos; (forward) 5&apos;- <br />                                              TTGCAACTGCTGCGTTAGCATGAG-3&apos; (reverse) GAPDH                                              5&apos;TGGCCAAGGTCATCCATGACAACT-3&apos; (forward) 5&apos;- <br />                                              CACAGTCTTCTGGGTGGCAGTGAT-3&apos; (reverse). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               immunoprecipitation <br />                                              HEK-293FT cells transfected V5 tagged LRRK2 Flag-tagged MKK <br />                                              constructs, harvested immunoprecipitation (IP) buffer consisted 150 mM NaCl, 20 <br />                                              mM Hepes (pH = 7.4), 50 mM &#206;&#178;-glycerophosphate, 5 mM sodium fluoride, 1% Triton <br />                                              X-100, 10% glycerol, 2 mM EGTA, 1 mM sodium orthovanadate, 1&#195;&#8212; protease inhibitor <br />                                              cocktail (Sigma) LRRK2-MKK3 immunoprecipitation 0.5% Triton-X, 1 mM <br />                                              EDTA 1X PBS 1X protease inhibitor cocktail (Sigma)  <br />                                              immunoprecipitations. lysates rotated 4 &#194;&#176;C 30 minutes followed                                              centrifugation 13,000g 10 minutes. supernatant pre-cleared Protein G <br />                                              Sepharose 4 Fast Flow (Amersham) followed addition appropriate antibody                                              rotated overnight 4 &#194;&#176;C. Protein G Sepharose added pull antibody pre- <br />                                              complex. Sepharose beads stringently washed times IP buffer                                              50 mM Tris (pH = 8) wash buffer. immunoprecipitation proteins eluted                                              lithium dodecyl sulphate (LDS) sample buffer (Invitrogen) heating 95 &#194;&#176;C 3 <br />                                              minutes. Immunoprecipitates resolved 3&#226;&#8364;&#8220;8% NuPAGE Tris-Acetate 4&#226;&#8364;&#8220;20% Tris- <br />                                              <span id='am-43' about='obo:IMR_0100118' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001695 obo:IMR_0000001 obo:IMR_0100116'><span id='am-44' property="oboInOwl:id" content="IMR:0100118" datatype="xsd:string"></span><span id='am-45' property="rdfs:label" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasExactSynonym" content="Glycine" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="glycine" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasExactSynonym" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasDbXref" content="KEGG:C00037" datatype="xsd:string"></span><span id='am-51' property="oboInOwl:hasAlternativeId" content="IMR:0200057" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:hasExactSynonym" content="Gly" datatype="xsd:string"></span><span id='am-53' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-54' property="rdfs:label" content="Gly" datatype="xsd:string"></span>Glycine</span> gels (Invitrogen) analyzed western blot. Antibodies purchased                                              Sigma (V5, Flag, c-Myc, actin), Calbiochem (Calnexin), Biodesign (GAPDH). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              immunoaffinity chromatography, lysates (5 mg) generated using IP buffer, <br />                                              loaded column containing 400 &#194;&#181;l anti-V5-agarose (Sigma), washed IP buffer <br />                                              followed 50 mM Tris (pH 8) wash buffer, eluted V5-<span id='am-1' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="peptide" datatype="xsd:string"></span><span id='am-3' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span>peptide</span> (1 mg/ml, <br />                                              Sigma). Fractions analyzed immunoblot described  <br />  <br />                               Subcellular fractionation <br />                                              HEK-293FT cells transfected appropriate constructs 48 hours, washed <br />                                              cold 1&#195;&#8212; PBS, lysed relaxation buffer consisted 100 mM KCl, 3 mM NaCl, <br />                                              3.5 mM MgCl2, 1.25 mM EGTA, 10 mM PIPES, 1&#195;&#8212; protease inhibitor cocktail.                                              lysates centrifuged 500g 5 minutes eliminate cellular debris,                                              supernatant centrifuged 100,000g 1 hour 4 &#194;&#176;C separate cytosolic <br />                                              fraction. pellets solublized 200 &#194;&#181;l relaxation buffer obtain membrane <br />  <br />  <br />                                                   J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                             Page 4 <br />  <br />  <br />                                            fraction. Equal amounts lysate loaded resolved 3&#226;&#8364;&#8220;8% NuPAGE Tris-Acetate <br />                                            4&#226;&#8364;&#8220;20% Tris-<span id='am-55' about='obo:IMR_0100118' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001695 obo:IMR_0000001 obo:IMR_0100116'><span id='am-56' property="oboInOwl:hasExactSynonym" content="Gly" datatype="xsd:string"></span><span id='am-57' property="rdfs:label" content="glycine" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-59' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:hasExactSynonym" content="Glycine" datatype="xsd:string"></span><span id='am-61' property="oboInOwl:id" content="IMR:0100118" datatype="xsd:string"></span><span id='am-62' property="rdfs:label" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasExactSynonym" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-64' property="rdfs:label" content="Gly" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasAlternativeId" content="IMR:0200057" datatype="xsd:string"></span><span id='am-66' property="oboInOwl:hasDbXref" content="KEGG:C00037" datatype="xsd:string"></span>Glycine</span> gels western blotting. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Kinase assays <br />                                            Kinase assays performed described Gloeckner et al (Gloeckner et al. 2009, <br />                                            Greggio et al. 2007). Recombinant LRRK2 obtained Invitrogen. MKKs                                            generated transfecting 293FT cells Flag-MKK constructs, immunopurifying                                            Flag-MKK anti-Flag M2 agarose eluting Flag peptide (25 &#194;&#181;g peptide/run, <br />                                            using 10 cm dish purification). 25 nM recombinant LRRK2 (Invitrogen)                                            incubated ~ 1&#194;&#181;M Flag-tagged MKK substrate protein 30 &#194;&#181;L assay buffer (25 mM <br />                                            Tris&#226;&#8364;&#8220;HCl pH 7.5, 5 mM beta-glycerophosphate, 2 mM DTT, 0.1 mM Na3VO4, 10 mM <br />                                            MgCl2, Cell Signaling) supplemented 5 &#194;&#181;Ci &#206;&#179;33P-<span id='am-32' about='obo:IMR_0001351' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-33' property="oboInOwl:hasExactSynonym" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasAlternativeId" content="IMR:0200394" datatype="xsd:string"></span><span id='am-35' property="rdfs:label" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-36' property="rdfs:label" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="KEGG:C00002" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-39' property="rdfs:label" content="ATP" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasAlternativeId" content="IMR:0100127" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:id" content="IMR:0001351" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasExactSynonym" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span>ATP</span> (3000 Ci/mmol; PerkinElmer <br />                                            Life Sciences). reaction mix incubated 1 h 30&#194;&#176;C. reaction stopped                                            addition 10 &#194;&#181;L 5 &#195;&#8212; Laemmli buffer samples incubated 5 min 95&#194;&#176;C prior                                            SDS gel-electrophoresis subsequent immunoblotting, needed. <br />  <br />                               Immunocytochemistry <br />                                            HEK-293FT cells plated glass coverslips transfected Lipofectamine 2000                                            50% confluency. 48 hours, transfected cells fixed 4% paraformaldehyde <br />                                            1&#195;&#8212; PBS 10 minutes room temperature. cells washed 3 times PBS 5 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            minutes incubated 0.3% triton X-100 PBS 1% bovine serum <br />                                            albumin (BSA) 1 hour room temperature. cells incubated 1:1000 <br />                                            dilution anti-V5 anti-FLAG antibodies overnight room temperature. washing <br />                                            cells 3 times PBS 5 minutes  cells incubated 1:750 dilution <br />                                            FITC-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch) 1&#195;&#8212; PBS.                                            washes repeated 1&#195;&#8212; PBS cells incubated 1:750 dilution Texas <br />                                            Red conjugated donkey anti-mouse antibody (Jackson ImmunoResearch). washing                                            cells 3 times 1&#195;&#8212; PBS 5 minutes  embedded Antifade DAPI gel <br />                                            mounting medium (Invitrogen). Antibody N-terminus APP (22C11, Calbiochem) <br />                                            used marker cell membranes. <br />  <br />                               Microscopy <br />                                            cells visualized dimensional multiple wavelength fluorescence <br />                                            microscopy using Olympus IX70 microscope equipped SoftWor&#195;&#8212; 3.3.6, Deltavision <br />                                            90000 (Applied Precision) DAPI, FITC Texas Red fluorescence room temperature <br />                                            using oil immersion 60&#195;&#8212; Olympus PlanApo objective (aperture set 1.40). images <br />                                            captured using HP CoolSNAP camera, deconvolved using SoftWor&#195;&#8212; software <br />                                            (Applied Precision), examined single sections projections entire stack <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            optical sections. images processed using Adobe Photoshop CS2. <br />  <br />                                            C. elegans&#226;&#8364;&#8221;Transgenic LRRK2 C. elegans lines generated described Saha et <br />                                            al (Saha et al. 2009). WT LRRK2 wlzIs2 line crossed sek-1 [km4] line                                            bred homozygocity (Tanaka-Hino et al. 2002). presence LRRK2 km4 <br />                                            deletion validated PCR. RNAi knockdown performed according Kamath et <br />                                            al. (Kamath et al. 2001). Non-transgenic Bristol N2 WT LRRK2 worms allowed                                            lay eggs 3 hours NGM plates containing OP50 bacteria. 3 days, synchronized <br />                                            young adult nematodes moved NGM plates feed HT115 bacteria containing <br />                                            vector PL4440 double-stranded RNAi expressing plasmid 2 additional <br />                                            days. 25 adult worms moved triplicate plates containing 25 &#194;&#181;M rotenone                                            HT115 bacteria. NGM plates 1 mM IPTG constant induction                                            RNAs. Nose-poke assays performed identify quantify live worms 4 days. <br />  <br />  <br />  <br />                                                 J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                            Page 5 <br />  <br />  <br />                               Statistical analysis <br />                                            data expressed mean &#194;&#177; SEM graphed using Excel Prism (GraphPad). <br />                                            way ANOVA Tukey&#226;&#8364;&#8482;s post hoc tests performed identify statistically <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            significant differences using InStat (GraphPad). <br />  <br />                               RESULTS <br />                               LRRK2 binds MKK3 6 <br />                                            HEK-293FT cells transiently transfected V5 tagged WT LRRK2 Flag- <br />                                            tagged MKK3 MKK6. Protein complexes containing MKK6 (Fig. 1  MKK3 (SI Fig. <br />                                            S2  evident immunoprecipitation LRRK2 MKKs. Interestingly, <br />                                            transfecting LRRK2 MKK6 increased total levels MKK6, shown                                            input lanes Fig. 1A &amp; C. Analysis LRRK2 deletion mutants demonstrated LRRK2 <br />                                            COR kinase domains essential sufficient binding MKK6 (Fig. 1 B)                                            MKK3 (Fig. S2 B). contrast, LRR domain required binding. Selectivity <br />                                            apparent study MKK mutants, dominant negative MKK <br />                                            mutation K82A strongly reduced binding LRRK2 MKK6 (Fig. 1 C) MKK3 <br />                                            (Fig. S2 D). Finally, examined LRRK2 associated endogenous MKK6. <br />                                            HEK-293 FT cells transfected vector V5-tagged wild-type LRRK2. <br />                                            Lysates collected immunoprecipitation buffer, passed anti-V5 column <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            eluted V5-peptide. Endogenous MKK6 readily apparent eluate V5- <br />                                            LRRK2 transfected lysates absent vector-transfected lysates (Fig.1D). <br />                                            Immuboblots cell lysates immunoprecipitation showed increase                                            endogenous MKK6 levels transfection LRRK2 (Fig. 1D), similar                                            increase observed Figures 1A &amp; C. results suggest LRRK2 interacts                                            MKK6 MKK3. <br />  <br />                               LRRK2 binds MKK7 MKK4 <br />                                            JNK pathway regulated MKK4 MKK7, hypothesize LRRK2 <br />                                            interact MKKs. immunoprecipitation experiments demonstrated <br />                                            LRRK2 binds MKK7 MKK4 (Fig. 2 . LRRK2 kinase COR <br />                                            domains essential sufficient interaction MKK7 (Fig. 2 B), similar                                            observed MKK6 MKK3. dominant negative K82A mutation completely <br />                                            abolished binding MKK7 LRRK2 (Fig. 2 C), suggesting similar                                            interaction MKK6 LRRK2, LRRK2/MKK7 interaction dependent                                            activation MKK7. observed transfecting LRRK2 MKK4 7                                            associated increase MKK levels similar seen MKK6 (Fig. 2A &amp; C). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               LRRK2 weakly phosphorylates MKKs <br />                                            association LRRK2 MKKs led hypothesize families                                            kinases potentially mutual substrates. Recent studies indicate LRRK2 <br />                                            phosphorylates recombinant MKKs (Gloeckner et al. 2009). test hypothesis, <br />                                            radioactive kinase assays performed using Flag-tagged MKK3, 6 7 <br />                                            immunoprecipitated HEK-293FT cells recombinant LRRK2 (fig. 3A &amp; B). <br />                                            Phosphorylation measured using 32P-ATP (fig. 3A, C &amp; D). Incubating WT G2019S <br />                                            LRRK2 MKK3, 6 7 moderately stimulated phosphorylation MKK3 MKK7, <br />                                            marginal effects MKK6 (fig. 3C). Phosphorylation required LRRK2 kinase <br />                                            activity kinase dead LRRK2 able stimulate MKK phosphorylation (fig. <br />                                            3A &amp; C). Interestingly, MKKs appeared reduce autophosphorylation                                            G2019S LRRK2 (fig. 3D). data provide evidence LRRK2 modify MKK <br />                                            function, vice-versa. phosphorylation modest, changes  <br />  <br />                                                 J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                             Page 6 <br />  <br />  <br />                                           phosphorylation downstream kinases, JNK p38, observed  <br />                                           expressing WT G2019S LRRK2 (data shown), consistent prior reports <br />                                           (Liou et al. 2008). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               expressing LRRK2 MKK6 increases levels MKK6 membrane                               cytoplasm <br />                                           activity MAPK cascades regulated factors phosphorylation. <br />                                           regulation MAPK specificity frequently requires tethering appropriate kinases <br />                                           scaffold proteins form stimuli-specific module, module targeted <br />                                           appropriate subcellular compartment activation downstream signals (Garrington <br />                                           &amp; Johnson 1999). hypothesized LRRK2 act scaffold protein                                           recruit MKKs specific subcellular compartments. test hypothesis, investigated <br />                                           expression LRRK2 altered distribution MKK6. HEK-293FT cells                                           transfected WT LRRK2 WT dominant negative MKK6, lysates <br />                                           fractionated cytosolic membrane fractions (Fig. 4A). Expressing WT LRRK2 <br />                                           increased levels MKK6 membrane fraction approximately 4-fold (Fig. 4 &amp; B). <br />                                           Total MKK6 levels increased expression LRRK2, increase <br />                                           (~50%) change seen membrane fraction (Fig. 4A). LRRK2 <br />                                           expression appeared somewhat reduced expressed dominant negative <br />                                           MKK6 compared WT MKK6, occurred cytoplasm membrane <br />                                           fractions (fig. 4A). examine subcellular localization MKKs, focused NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           interaction MKK6 using imaging, performed immunocytochemistry utilizing                                           antibody N-terminus amyloid precursor protein (22C11) <span id='am-67' about='rdfs:label' typeof='owl:Thing'>label</span> membrane. <br />                                           localization MKK6 membrane marker (amyloid precursor protein) increased <br />                                           cells transfected LRRK2 MKK6, compared cells expressing MKK6                                           (fig. 4C); pattern reactivity suggested localization plasma membrane. <br />  <br />                                           examined expression MKK6 changed subcellular localization <br />                                           LRRK2. fractionation studies showed increases cytoplasmic membrane <br />                                           levels LRRK2 (fig. 4A). proceeded examine question                                           Immunocytochemistry. Cells expressed LRRK2 MKK6 showed pattern                                           reactivity distinct &#226;&#8364;&#339;rim&#226;&#8364;? reactivity, compared cells expressing LRRK2 <br />                                           cells expressing dnMKK6 (fig. 5). data consistent increased membrane <br />                                           binding, MKK6 increases total levels LRRK2, microscopy                                           rule changes result simply increased expression. <br />  <br />                               MKK6 p38 orthologs C. elegans required LRRK2 function <br />                                           gain insight role MKK6 LRRK2 function vivo examine NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           endogenous MKKs regulated LRRK2 function neurons, utilized transgenic C. elegans <br />                                           lines express human WT LRRK2 driven synaptobrevin promoter,                                           neuron-specific promoter. recently generated lines C. elegans expressing LRRK2                                           showed LRRK2 complements function C. elegans ortholog, lrk-1                                           rotenone-protection assay (Saha et al. 2009). Nematode lines expressing WT LRRK2                                           strongly protected toxicity rotenone, mitochondrial complex inhibitor (Saha et <br />                                           al. 2009). strong phenotype associated LRRK2 expression provides robust assay <br />                                           test genetic pathways mediating LRRK2 function. <br />  <br />                                           RNAi used knock C. elegans MKK6/3 ortholog sek-1 downstream <br />                                           target, p38 MAPK ortholog pmk-1. Non-transgenic Bristol N2 WT LRRK2 C. elegans <br />                                           exposed RNAi feeding vectors coding sek-1 pmk-1 exposed 25 <br />                                           &#194;&#181;M rotenone 4 days maintaining RNAi treatment. observed nematodes <br />                                           expressing LRRK2 protected rotenone (Fig. 6), consistent  <br />  <br />                                                J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                            Page 7 <br />  <br />  <br />                                          prior results (Saha et al. 2009). Knockdown sek-1 (Fig. 6A) pmk-1 (Fig. 6B) <br />                                          completely abolished ability WT LRRK2 protect C. elegans rotenone, <br />                                          control vector effect. Analysis mRNA levels real time PCR <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          indicated 60 &#194;&#177; 9% (P &lt; 0.01, N=3) decrease expression sek-1 transcript                                          similar decrease pmk-1. role MKK3/6 (sek-1) confirmed deleting                                          sek-1 gene WT LRRK2 wlzIs2 crossing sek-1 [km4] C. elegans line, <br />                                          carries deletion sek-1 exons 4&#226;&#8364;&#8220;6 (www.wormbase.org), breeding                                          homozygocity (Tanaka-Hino et al. 2002). effects rotenone toxicity                                          examined. LRRK2 wlzIs2 line showed strong resistance rotenone toxicity,                                          LRRK2/sek-1 [km4] line showed protection (Fig. 6C). Finally, examined                                          endogenous lrk-1 required protection sek1 pmk-1. determine sek-1 <br />                                          pmk-1 required lrk-1 modify rotenone toxicity, examined effects sek-1                                          pmk-1 knockdown lrk-1 [km17] C. elegans line deletion lrk-1. lrk-1 <br />                                          [km17] line highly sensitive rotenone (25 &#194;&#181;M, 4 days), expected. addition, <br />                                          pmk-1 knockdown provided protection effect sek-1 knockdown                                          observed N2 line contains active lrk-1 (fig. 6D lrk-1[km17] line, vs. <br />                                          fig. 6A&amp;B lines containing lrk-1). Taken data suggest lrk-1                                          LRRK2 require sek-1 pmk-1 action  C. elegans homologues MKK6 p38), <br />                                          vice versa. <br />  <br />                               Disease-linked mutations LRRK2 modify binding <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          Finally, tested mutations LRRK2 associated disease modified <br />                                          interaction LRRK2 MKKs. HEK 293 cells transfected LRRK2 <br />                                          (WT, G2019S, R1441C, Y1699C I2020T) MKK6. LRRK2                                          immunoprecipitated binding MKK6 quantified immunoblot (Fig. 7A &amp; B).                                          G2019S, R1441C I2020T mutations enhanced binding LRRK2 MKK6,                                          Y1699C mutation did alter binding (Fig. 7 &amp; B). enhanced binding                                          mutant LRRK2 exerted stronger effects MKK6 MKK3 7 binding; R1441C <br />                                          G2019S mutations did statistically significant increases binding LRRK2 <br />                                          MKK7 (Fig. 7 C &amp; D) MKK3 (Fig. S2 C). <br />  <br />                               DISCUSSION <br />                                          results indicate LRRK2 interacts MKK3, 6 7. provide multiple <br />                                          independent lines investigation supporting hypothesis LRRK2 interacts                                          MKKs. LRRK2 binds MKK3, 6, 7, R1441C LRRK2 mutation increases <br />                                          binding MKK6. LRRK2 phosphorylates MKK3 MKK7 vitro relatively <br />                                          minor effect MKK6 phosphorylation. expression LRRK2 MKK6 increased <br />                                          levels protein observed expression protein   <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          expression increased levels LRRK2 MKK6 membrane                                          cytoplasm. Membrane localization LRRK2 MKK6 evident using biochemical <br />                                          fractionation, immunocytochemical studies. Finally, cellular studies                                          complemented studies showing knockdown deletion MKK6 (sek-1) p38 <br />                                          (pmk-1) C. elegans abrogates LRRK2-mediated protection rotenone toxicity, <br />                                          demonstrates endogenous MKK6 required LRRK2 function.  <br />                                          data point role MKKs JNK/p38 pathways LRRK2 function.                                          data consistent hypothesis interaction MKKs LRRK2 affects <br />                                          different biochemical processes, protein translation  degradation) membrane <br />                                          association. <br />  <br />                                          observed robust binding LRRK2 MKK3, 6 7, MKK4. structures <br />                                          MKK4 MKK2 differ N-termini, conserved,                                          short sequences (MKK4 amino acids 193-9, 278&#226;&#8364;&#8220;283 329-35) conserved  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                          Page 8 <br />  <br />  <br />                                         MKK 3, 6 7 MKK4. Future studies determine                                         domains contribute specificity LRRK2 binding. domains LRRK2 regulate <br />                                         binding identified deletion studies showed similar binding patterns MKK3, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         6 7. MKKs bound LRRK2 deletion constructs containing COR                                         kinase domains, LRR domain LRRK2. studies highlight                                         importance ROC COR domains. ROC domain LRRK2 contributes                                         homo-dimerization (Greggio et al. 2008), sequences outside ROC-COR bi- <br />                                         domain required dimer formation (Klein et al. 2009, Greggio et al. 2008). <br />                                         LRRK2 binds CHIP, ubiquitin ligase binds Hsp-70, interaction occurs                                         COR ROC domains (Ko et al. 2009). ROC COR domains  kinase <br />                                         domain) necessary phosphorylation moesin (Jaleel et al. 2007).                                         putative LRRK2 binding proteins identified, including Fas binding <br />                                         protein, Hsp90, 4E-BP JIP1-4, studies analyzed domain <br />                                         requirements binding (Ho et al. 2009, Dachsel et al. 2007, Imai et al. 2008, Hsu et al. <br />                                         2009).  ROC COR domains appear play particularly important roles                                         association LRRK2 proteins. <br />  <br />                                         study identifies new group proteins regulate levels LRRK2                                         membrane association LRRK2. expressing LRRK2 MKKs increased total <br />                                         levels LRRK2 MKKs (fig. 1, 2 &amp; 4). hypothesize changes regulated <br />                                         level translation degradation expression increased NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         transgenic proteins (LRRK2 MKKs), regulated constitutive CMV <br />                                         promoter, endogenous MKK6 (fig. 1). Prior studies indicate LRRK2 binds                                         protein 4E-BP, inhibits protein translation, stimulating 4E-BP                                         <span id='am-6' about='obo:IMR_0002818' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-7' property="rdfs:label" content="rapamycin" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:id" content="IMR:0002818" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasDbXref" content="KEGG:C07909" datatype="xsd:string"></span>rapamycin</span> suppress phenotypes associated PD (Imai et al. 2008,Tain et al. 2009). <br />                                         recently confirmed LRRK2 phosphorylates 4E-BP, phosphorylation <br />                                         observed vitro, cell systems (Kumar et al. 2009). Interestingly,                                         p38, potential effector MKK activity convincing kinase                                         LRRK2 4EBP. direct mediated intermediate kinases, interaction <br />                                         LRRK2 4E-BP provides link LRRK2 protein translation                                         contribute changes LRRK2 levels associated expressing MKKs.                                         studies needed clarify LRRK2 complex includes MKKs 4E- <br />                                         BP proteins linked protein translation. <br />  <br />                                         LRRK2 localizes membranes significance localization poorly <br />                                         understood (West et al. 2005, Biskup et al. 2006, Higashi et al. 2007). studies suggest <br />                                         transfecting LRRK2 MKK6  possibly MKKs) increases membrane <br />                                         association MKK6. increase LRRK2 membrane localization <br />                                         remains ambiguous increase total LRRK2 associated MKK  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         transfection account apparent increase LRRK2 membrane localization. <br />                                         hypothesis association LRRK2 membranes regulate <br />                                         localization proteins new, multiple prior studies provide clear evidence                                         localization LRRK2 membranes. Studies Hatana et al. (Hatano et al. 2007) <br />                                         indicate LRRK2 localizes plasma membrane <span id='am-19' about='obo:IMR_0001362' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-20' property="rdfs:label" content="lipid" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-22' property="obo:IAO_0000115" content="Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent." datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasDbXref" content="CHEBI:25054" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:id" content="IMR:0001362" datatype="xsd:string"></span>lipid</span> rafts, studies                                         groups demonstrate LRRK2 associates organelle membranes (West et al. <br />                                         2005, Biskup et al. 2006, Higashi et al. 2007). observation LRRK2 regulates MKK <br />                                         localization complements recent studies laboratory indicating LRRK2 <br />                                         binds JIP1 &#226;&#8364;&#8220; 4, scaffold proteins bring MKKs MAPKs (e.g., <br />                                         JNK p38) (Hsu et al. 2009). JIPs appear function directing MAP kinase <br />                                         signaling complex different sites cells (Whitmarsh 2006). hypothesize                                         LRRK2 acts complex facilitate localization MKK/MAPK proteins                                         sites stress. <br />  <br />  <br />  <br />                                              J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                          Page 9 <br />  <br />  <br />                                         actions LRRK2 appear differ RIPs MLKs, despite moderate <br />                                         homology proteins. RIPs MLKs thought function multi-tiered <br />                                         phosphorylating appropriate downstream MAPKK, turn <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         phosphorylates activates JNK p38 regulate specific transcription factors                                         cellular responses. contrasts relatively modest phosphorylation                                         MKKs LRRK2. able repeat observations Gloeckner et al showing                                         LRRK2 phosphorylates MKKs 3, 6 7.  concentration MKKs needed                                         elicit phosphorylation MKKs quite high (40-fold greater LRRK2),                                         suggests small fraction MKK actually phosphorylated LRRK2, <br />                                         reminiscent recent observations low level 4EBP phosphorylation LRRK2.                                         low level phosphorylation explain changes MKK, JNK p38 <br />                                         phosphorylation evident transfection proteins. <br />  <br />                                         modest effects kinase domain consistent results observed C. elegans <br />                                         Drosophila (Saha et al. 2009, Wang et al. 2008). C. elegans, kinase <br />                                         dead LRRK2 functional protected toxicity induced rotenone, <br />                                         WT LRRK2 (Saha et al. 2009). Similar results observed                                         Drosophila, Wang colleagues observed deletion kinase domain                                         Drosophila LRRK2 homolog protected toxicity induced rotenone paraquat <br />                                         (Wang et al. 2008). studies suggest LRRK2 exhibits multiple physiological <br />                                         actions, independent kinase activity. type kinase-independent <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         regulation similar observed RIP kinases, closest homologues                                         LRRK2 (Festjens et al. 2007). RIP-1 activates NF-kB response DNA damage                                         mechanism does require RIP-1 kinase activity (Festjens et al. 2007).                                          pathways regulated RIP-1, TNF-receptor/MEK-1/ERK cascade, require <br />                                         RIP-1 kinase activity (Festjens et al. 2007). <br />  <br />                                         Studies LRRK2 beginning illuminate functional role LRRK2. Experiments                                         mammalian cells indicate LRRK2 potentiates peroxide-induced neurotoxicity                                         kinase dependent manner (West et al. 2007). studies vivo support role LRRK2 <br />                                         response stress, differ details (Saha et al. 2009, Wang et al. 2008).                                         observed WT LRRK2 protects toxicity induced rotenone paraquat C. <br />                                         elegans, inhibit complex electron transport chain (Saha et al. 2009). <br />                                         G2019S R1441C LRRK2 mutants reduced protection mitochondrial <br />                                         inhibition actually increase degeneration dopaminergic neurons basal <br />                                         conditions mitochondrial inhibition (Saha et al. 2009). LRRK2 expression C. <br />                                         elegans complements function lrk-1, homolog LRRK2 C. elegans,                                         knockdown deletion lrk-1 potentiates rotenone toxicity (Saha et al. 2009, Sakaguchi- <br />                                         Nakashima et al. 2007). Wang colleagues observed similar results, study <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         pointed selective role LRRK2 protecting toxicity induced hydrogen <br />                                         peroxide (Wang et al. 2008). selective toxicity observe mutant LRRK2                                         consistent studies transgenic mice, rats neuronal SY5Y cells suggest <br />                                         mutant forms LRRK2 toxic WT LRRK2 (Li et al. 2009, Greggio <br />                                         et al. 2006, Greggio et al. 2007, Macleod et al. 2006, Smith et al. 2005). current <br />                                         manuscript, extend observations demonstrating LRRK2-mediated stress <br />                                         response requires activity MKK6/sek-1 p38/pmk-1 pathway, blocking <br />                                         pathway abrogated protection LRRK2 C. elegans. Knockdown MKK6/sek-1                                         p38/pmk-1 protects rotenone-mediated toxicity non-transgenic nematodes,                                         brings protection level equal seen LRRK2 expression. Conversely, <br />                                         knockdown MKK6/sek-1 p38/pmk-1 LRRK2 nematodes effectively abrogates                                         protection LRRK2 brings protection level non-transgenic nematodes. <br />                                         data consistent hypothesis LRRK2 acts mechanism involving <br />                                         MKK6/sek-1 p38/pmk-1. <br />  <br />  <br />                                              J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                                              Page 10 <br />  <br />  <br />                                           MAPK cascade contributes disease remains unclear. current study,                                           G2019S, R1441C I2020T LRRK2 mutant constructs showed increased binding                                           MKKs, Y1699C LRRK2 mutation did statistically significant <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           increase binding. Binding MKK3 7 did statistically significant changes, <br />                                           apparent mutation-linked differences raises possibility future studies <br />                                           using larger sample sizes identify significant effects. results parallel                                           binding studies, identify specific binding interaction altered large <br />                                           panel disease-linked mutations (Imai et al. 2008, Ko et al. 2009, Ho et al. 2009, Dachsel <br />                                           et al. 2007, Jaleel et al. 2007); (Hsu et al. 2009). Studies phosphorylation inclusion <br />                                           formation effects consistent disease-linked mutations <br />                                           (Greggio et al. 2006, Greggio et al. 2007, Smith et al. 2005, Gloeckner et al. 2009, Greggio <br />                                           et al. 2008, Ito et al. 2007, West et al. 2005). notable exception trend binding <br />                                           LRRK2 Fas-associated protein, does robust increases binding                                           panel different LRRK2 mutations (Ho et al. 2009). Fas-associated protein <br />                                           utilizes signal transduction pathway mediated RIP kinases mediated MKKs <br />                                           (Festjens et al. 2007).  Fas-mediated pathway involving MKKs contribute                                           pathophysiology PD, information needed conclusion <br />                                           stated strong confidence. <br />  <br />                                           increasing evidence linking LRRK2 function stress response, particular                                           MAPK pathways, illuminates biological function ultimately reveal <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           biological mechanisms linked PD. studies shown p38 JNK actions                                           crucial regulation cell death PD models. CHOP/Gadd153, transcription factor <br />                                           downstream p38, regulated 6-OHDA 1-methyl-4-phenylpyridinium <br />                                           (MPP+) treatments dopaminergic cell line. Manganese 6-OHDA treatments                                           strongly activate p38 JNK pathways increasing phosphorylated p38 c-jun (Holtz <br />                                           &amp; O&apos;Malley 2003). c-Jun activated dopaminergic neurons PD patients 1- <br />                                           methyl-4-phenyl-1,2,4,6 tetrahydropyridine (MPTP) mouse model PD. JNK2 JNK3, <br />                                           JNK 1, required MPTP-induced c-jun activation elimination <br />                                           JNK2 JNK3 prevent neurodegeneration improve motor function MPTP-treated <br />                                           mice (Hunot et al. 2004). Inhibitors JNK MLK CEP1347 shown                                           protective various vitro vivo PD models (Roux et al. 2002, Silva et al. 2005). <br />                                           data suggest role LRRK2 p38 JNK cascades response stresses <br />                                           related PD. <br />  <br />                               Supplementary Material <br />                                           Refer Web version PubMed Central supplementary material. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Acknowledgments <br />                                           thank Roger Davis generosity sharing MKK plasmids, Leonard Petrucelli valuable <br />                                           advice. thank Shelley Russek Ramona Faris assistance luciferase assays, Andrew <br />                                           Ferree help editing manuscript. work supported NIEHS ES15567, NINDS NS41786,                                           Alzheimer Association Michael J. Fox Foundation (B.W.). research supported                                           Intramural Research Program NIH, National Institute Aging, Z01AG000948 (M.R.C.). <br />  <br />  <br />                               ABBREVIATIONS <br />                                         COR              carboxy-terminal Ras <br />                                         JIP              c-Jun interacting protein <br />                                         JNK              c-Jun kinase <br />  <br />  <br />  <br />                                                 J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                                   Page 11 <br />  <br />  <br />  <br />  <br />                                         LRRK2           leucine-rich repeat kinase 2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         MAPK            mitogen-activating protein kinase, MAPK <br />                                         MKK             MAPK kinase <br />                                         MLK             mixed-lineage kinase <br />                                         PD              Parkinson&#226;&#8364;&#8482;s disease <br />                                         RIP             Receptor Interacting Protein kinase <br />                                         ROC             Ras complex <br />  <br />                               REFERENCES <br />                                           Biskup S, Moore DJ, Celsi F, et al. Localization LRRK2 membranous vesicular structures                                             mammalian brain. Ann Neurol 2006;60:557&#226;&#8364;&#8220;569. [PubMed: 17120249] <br />                                           Dachsel JC, Taylor JP, Mok SS, et al. Identification potential protein interactors Lrrk2. <br />                                             Parkinsonism Relat Disord 2007;13 <br />                                           Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, kinase crossroads cell&apos;s <br />                                             decision live die. Cell Death Differ 2007;14:400&#226;&#8364;&#8220;410. [PubMed: 17301840] <br />                                           Gallo KA, Johnson GL. Mixed-lineage kinase control JNK p38 MAPK pathways. Nat Rev Mol <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Cell Biol 2002;3:663&#226;&#8364;&#8220;672. [PubMed: 12209126] <br />                                           Garrington TP, Johnson GL. Organization regulation mitogen-activated protein kinase signaling <br />                                             pathways. Curr Opin Cell Biol 1999;11:211&#226;&#8364;&#8220;218. [PubMed: 10209154] <br />                                           Gloeckner CJ, Schumacher  Boldt K, Ueffing M. Parkinson disease-associated protein kinase <br />                                             LRRK2 exhibits MAPKKK activity phosphorylates MKK3/6 MKK4/7, vitro. J <br />                                             Neurochem 2009;109:959&#226;&#8364;&#8220;968. [PubMed: 19302196] <br />                                           Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations Parkinson&apos;s disease:                                             questions. ASN Neuro 2009;1 <br />                                           Greggio E, Jain S, Kingsbury  et al. Kinase activity required toxic effects mutant <br />                                             LRRK2/dardarin. Neurobiol Dis 2006;23:329&#226;&#8364;&#8220;341. [PubMed: 16750377] <br />                                           Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich  Ding J, Beilina  Baker AK, <br />                                             Cookson MR. Mutations LRRK2/dardarin associated Parkinson disease toxic                                             equivalent mutations homologous kinase LRRK1. J Neurochem 2007;102:93&#226;&#8364;&#8220;102. [PubMed: <br />                                             17394548] <br />                                           Greggio E, Zambrano  Kaganovich  et al. Parkinson disease-associated leucine-rich repeat <br />                                               kinase 2 (LRRK2) dimer undergoes intramolecular autophosphorylation. J Biol Chem <br />                                               2008;283:16906&#226;&#8364;&#8220;16914. [PubMed: 18397888] <br />                                           Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N. Leucine-rich repeat kinase 2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               associates lipid rafts. Hum Mol Genet 2007;16:678&#226;&#8364;&#8220;690. [PubMed: 17341485] <br />                                           Higashi S, Moore DJ, Colebrooke  Biskup S, Dawson VL, Arai H, Dawson TM, Emson PC. <br />                                               Expression localization Parkinson&apos;s disease-associated leucine-rich repeat kinase 2                                               mouse brain. J Neurochem 2007;100:368&#226;&#8364;&#8220;381. [PubMed: 17101029] <br />                                           Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. Parkinson disease protein leucine-rich repeat <br />                                               kinase 2 transduces death signals Fas-associated protein death domain caspase-8                                               cellular model neurodegeneration. J Neurosci 2009;29:1011&#226;&#8364;&#8220;1016. [PubMed: 19176810] <br />                                           Holtz WA, O&apos;Malley KL. Parkinsonian mimetics induce aspects unfolded protein response death <br />                                               dopaminergic neurons. J Biol Chem 2003;278:19367&#226;&#8364;&#8220;19377. [PubMed: 12598533] <br />                                           Hsu C, Chan D, Wolozin B. LRRK2 Stress Response: Interaction MKKs JIPs. <br />                                               Neurodegener Dis. 2009  press). <br />                                           Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA. JNK- <br />                                               mediated induction cyclooxygenase 2 required neurodegeneration mouse model                                               Parkinson&apos;s disease. Proc Natl Acad Sci U S 2004;101:665&#226;&#8364;&#8220;670. [PubMed: 14704277] <br />  <br />  <br />  <br />                                                 J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                                 Page 12 <br />  <br />  <br />                                         Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms mutant <br />                                             LRRK2-mediated cell death. Hum Mol Genet 2007;16:1319&#226;&#8364;&#8220;1326. [PubMed: 17409193] <br />                                         Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. Phosphorylation 4E-BP NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             LRRK2 affects maintenance dopaminergic neurons Drosophila. Embo J 2008;27:2432&#226;&#8364;&#8220; <br />                                             2443. [PubMed: 18701920] <br />                                         Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T. <span id='am-11' about='obo:IMR_0001354' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-12' property="rdfs:label" content="GTP" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasExactSynonym" content="guanosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0001354" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-16' property="rdfs:label" content="guanosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:hasAlternativeId" content="IMR:0200086" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="KEGG:C00044" datatype="xsd:string"></span>GTP</span> Binding Essential                                             Protein Kinase Activity LRRK2, Causative Gene Product Familial Parkinson&apos;s Disease. <br />                                             Biochemistry 2007;46:1380&#226;&#8364;&#8220;1388. [PubMed: 17260967] <br />                                         Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel  Alessi DR. LRRK2 <br />                                             phosphorylates moesin threonine-558: characterization Parkinson&apos;s disease mutants <br />                                             affect kinase activity. Biochem J 2007;405:307&#226;&#8364;&#8220;317. [PubMed: 17447891] <br />                                         Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J. Effectiveness specific RNA- <br />                                             mediated interference ingested double-stranded RNA Caenorhabditis elegans. Genome <br />                                             Biol 2001;2 RESEARCH0002. <br />                                         Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ. Homo- heterodimerization                                             ROCO kinases: LRRK2 kinase inhibition LRRK2 ROCO fragment. J Neurochem <br />                                             2009;111:703&#226;&#8364;&#8220;715. [PubMed: 19712061] <br />                                         Ko HS, Bailey R, Smith WW, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, <br />                                             degradation, toxicity. Proc Natl Acad Sci U S 2009;106:2897&#226;&#8364;&#8220;2902. [PubMed: 19196961] <br />                                         Kumar  Greggio E, Beilina  Kaganovich  Chan D, Wolozin B, Cookson M. Parkinson&#226;&#8364;&#8482;s <br />                                             disease associated LRRK2 exhibits weaker vitro phosphorylation 4E-BP compared                                             autophosphorylation. PLoS  2009  press). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Lewis PA, Greggio E, Beilina  Jain S, Baker  Cookson MR. R1441C mutation LRRK2 <br />                                             disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007;357:668&#226;&#8364;&#8220;671. [PubMed: <br />                                             17442267] <br />                                         Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue  Leucine-rich repeat kinase 2 (LRRK2)/ <br />                                             PARK8 possesses GTPase activity altered familial Parkinson&apos;s disease R1441C/G <br />                                             mutants. J Neurochem 2007;103:238&#226;&#8364;&#8220;247. [PubMed: 17623048] <br />                                         Li Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal <br />                                             features Parkinson&apos;s disease. Nat Neurosci. 2009 <br />                                         Liou AK, Leak RK, Li L, Zigmond MJ. Wild-type LRRK2 mutant attenuates stress-induced <br />                                             cell death ERK pathway. Neurobiol Dis 2008;32:116&#226;&#8364;&#8220;124. [PubMed: 18675914] <br />                                         Livak KJ, Schmittgen TD. Analysis relative gene expression data using real-time quantitative PCR <br />                                             2(&#226;&#710;&#8217;Delta Delta C(T)) Method. Methods 2001;25:402&#226;&#8364;&#8220;408. [PubMed: 11846609] <br />                                         Macleod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich  Familial Parkinsonism <br />                                             Gene LRRK2 Regulates Neurite Process Morphology. Neuron 2006;52:587&#226;&#8364;&#8220;593. [PubMed: <br />                                             17114044] <br />                                         Olanow CW, Stern MB, Sethi K. scientific clinical basis treatment Parkinson <br />                                             disease (2009). Neurology 2009;72:S1&#226;&#8364;&#8220;S136. [PubMed: 19470958] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT. Role autophagy G2019S-LRRK2-associated neurite <br />                                             shortening differentiated SH-SY5Y cells. J Neurochem 2008;105:1048&#226;&#8364;&#8220;1056. [PubMed: <br />                                             18182054] <br />                                         Roux PP, Dorval G, Boudreau M, Angers-Loustau  Morris SJ, Makkerh J, Barker PA. K252a                                             CEP1347 neuroprotective compounds inhibit mixed-lineage kinase-3 induce <br />                                             activation Akt ERK. J Biol Chem 2002;277:49473&#226;&#8364;&#8220;49480. [PubMed: 12388555] <br />                                         Saha S, Guillily M, Ferree  et al. LRRK2 modulates vulnerability mitochondrial dysfunction C. <br />                                             elegans. J. Neuroscience. 2009 press. <br />                                         Sakaguchi-Nakashima  Meir JY, Jin Y, Matsumoto K, Hisamoto N. LRK-1, C. elegans PARK8- <br />                                             related kinase, regulates axonal-dendritic polarity SV proteins. Curr Biol 2007;17:592&#226;&#8364;&#8220;598. <br />                                             [PubMed: 17346966] <br />                                         Silva RM, Kuan CY, Rakic P, Burke  Mixed lineage kinase-c-jun N-terminal kinase signaling <br />                                             pathway: new therapeutic target Parkinson&apos;s disease. Mov Disord 2005;20:653&#226;&#8364;&#8220;664. [PubMed: <br />                                             15719422] <br />  <br />  <br />  <br />                                              J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                                 Page 13 <br />  <br />  <br />                                         Smith WW, Pei  Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity mutant LRRK2 <br />                                             mediates neuronal toxicity. Nat Neurosci 2006;9:1231&#226;&#8364;&#8220;1233. [PubMed: 16980962] <br />                                         Smith WW, Pei  Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Leucine-rich repeat kinase 2 (LRRK2) interacts parkin mutant LRRK2 induces neuronal <br />                                             degeneration. Proc Natl Acad Sci U S 2005;102:18676&#226;&#8364;&#8220;18681. [PubMed: 16352719] <br />                                         Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation 4E- <br />                                             BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009;12:1129&#226;&#8364;&#8220;1135. [PubMed: <br />                                             19684592] <br />                                         Tanaka-Hino M, Sagasti  Hisamoto N, Kawasaki M, Nakano S, Ninomiya-Tsuji J, Bargmann CI, <br />                                             Matsumoto K. SEK-1 MAPKK mediates Ca2+ signaling determine neuronal asymmetric <br />                                             development Caenorhabditis elegans. EMBO Rep 2002;3:56&#226;&#8364;&#8220;62. [PubMed: 11751572] <br />                                         Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, Zhang  Dispensable role Drosophila <br />                                             ortholog LRRK2 kinase activity survival dopaminergic neurons. Mol Neurodegener <br />                                             2008;3:3. [PubMed: 18257932] <br />                                         West AB, Moore DJ, Biskup S, Bugayenko  Smith WW, Ross CA, Dawson VL, Dawson TM. <br />                                             Parkinson&apos;s disease-associated mutations leucine-rich repeat kinase 2 augment kinase activity. <br />                                             Proc Natl Acad Sci U S 2005;102:16842&#226;&#8364;&#8220;16847. [PubMed: 16269541] <br />                                         West AB, Moore DJ, Choi C, et al. Parkinson&apos;s disease-associated mutations LRRK2 link enhanced <br />                                             GTP-binding kinase activities neuronal toxicity. Hum Mol Genet 2007;16:223&#226;&#8364;&#8220;232. <br />                                             [PubMed: 17200152] <br />                                         Whitmarsh AJ. JIP family MAPK scaffold proteins. Biochem Soc Trans 2006;34:828&#226;&#8364;&#8220;832. <br />                                             [PubMed: 17052208] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Zimprich  Biskup S, Leitner P, et al. Mutations LRRK2 Cause Autosomal-Dominant <br />                                             Parkinsonism Pleomorphic Pathology. Neuron 2004;44:601&#226;&#8364;&#8220;607. [PubMed: 15541309] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                   Page 14 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fig. 1. <br />                                         LRRK2 binds MKK6, pathogenic mutations LRRK2 increase binding                                         LRRK2 MKK6. LRRK2 activates p38 pathway.   LRRK2 immunoprecipitates <br />                                         MKK6 HEK-293FT cells. (B) LRRK2 kinase COR domains essential NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         sufficient interaction MKK6. (C) Dominant negative K82A mutation MKK6 <br />                                         reduces MKK6 binding LRRK2. experiments performed times. D.) <br />                                         Eluate anti-V5 column shows association endogenous MKK6 LRRK2 <br />                                         (V5). Levels protein lysates shown  <br />  <br />  <br />  <br />  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                    Page 15 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fig. 2. <br />                                         LRRK2 binds MKK7 MKK4 activates JNK pathway.   LRRK2  <br />                                         immunoprecipitates MKK7 MKK4 HEK-293FT cells. (B) LRRK2 kinase <br />                                         COR domains essential sufficient interaction MKK7. (C) Dominant <br />                                         negative K82A mutation MKK7 reduces MKK7 binding LRRK2. experiments                                         performed times. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                   Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fig. 3. <br />                                         LRRK2 stimulates MKK phosphorylation.  Recombinant MKK3, 6 7 (Flag-tagged) <br />                                         incubated &#194;&#177; LRRK2 (WT, G2019S KD, GST-tagged), presence kinase <br />                                         buffer 32P-ATP. B. Coomassie gel showing purity recombinant MKK3, 6                                         7. C &amp; D. Quantification MKK phosphorylation (C) LRRK2 autophosphorylation (D) <br />                                         densitometry. Error bars SEM independent experiments. <br />  <br />  <br />  <br />  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                    Page 17 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fig. 4. <br />                                         Expressing LRRK2 increases level MKK6 membrane fraction.   WT <br />                                         G2019S LRRK2 increased level membrane MKK6. (B) Quantification indicated <br />                                         level membrane MKK6 increased 4-fold expressed                                         LRRK2 (*p&lt;0.05; N=3, compared WT MKK6). significant difference                                         level membrane MKK6 WT G2019S LRRK2-transfected samples.                                         level MKK6 membrane fraction normalized level MKK6 total <br />                                         lysate, compared samples transfected &#194;&#177; LRRK2. Experiments repeated <br />                                         times HEK-293FT cells. (C) expression WT G2019S LRRK2 WT <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         MKK6 increased levels MKK6 present plasma membrane, shown  <br />                                         localization amyloid precursor protein (APP). arrows point LRRK2/APP  <br />                                         localization. Bar, 15 &#194;&#181;m. experiments performed times. <br />  <br />  <br />  <br />  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                   Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fig. 5. <br />                                         expression LRRK2 MKK6 leads localization. HEK 293 cells  <br />                                         transfected LRRK2 (WT G2019S) &#194;&#177; MKK6 (WT dominant negative).                                         proteins subsequently identified immunocytochemistry. WT G2019S LRRK2 <br />                                         localize WT MKK6. localization reduced dominant negative MKK6, <br />                                         suggesting importance MKK6 function interaction LRRK2. arrows <br />                                         point areas LRRK2 membrane localization. Bar, 15 &#194;&#181;m. experiments                                         performed times. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               J Neurochem. Author manuscript; available PMC 2010 April 20. <br />                             Hsu et al.                                                                                          Page 19 <br /> NIH-PA <br /> </body></html>